<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01203462</url>
  </required_header>
  <id_info>
    <org_study_id>2010-402</org_study_id>
    <nct_id>NCT01203462</nct_id>
  </id_info>
  <brief_title>The PRIDE Study Probiotics on Regulation and Improving Digestive hEalth</brief_title>
  <acronym>PRIDE</acronym>
  <official_title>A Probiotic Double-blind Randomized Placebo Crossover Trial of Colonic Transit Time in Adult Females, The PRIDE Study The Study to Determine the Effects of Probiotics on Regulation and Improving Digestive hEalth</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Georgetown University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cargill</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Georgetown University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of probiotic supplemented yogurt in&#xD;
      reducing colonic transit time (CTT) in females between the ages of 18-65 years old. Two&#xD;
      yogurts will be administered, one containing a specific strain of probiotic in the&#xD;
      Bifidobacterium genus and the other without the probiotic supplement. It is hypothesized that&#xD;
      subjects receiving the probiotic supplemented yogurt will experience reduced CTT and improved&#xD;
      gastrointestinal comfort and quality of life compared to those receiving the non-probiotic&#xD;
      supplemented yogurt.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Colonic Transit Time</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of bowel movements (daily)</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool consistency (daily)</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Well being as assessed by agreed upon quality of life instrument</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dietary intake survey</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance</measure>
    <time_frame>90 days</time_frame>
    <description>by questionnaire: e.g. bloating</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rome criteria</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bristol criteria</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recovery of the probiotic in the faeces (quantitative measure)</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bacterial composition of the fecal flora</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Digestive Irregularity</condition>
  <condition>Digestive Discomfort</condition>
  <condition>History of Straining During Bowel Movements</condition>
  <condition>History of Hard or Lumpy Stools</condition>
  <arm_group>
    <arm_group_label>Bifidobacterium supplemented yogurt</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bifidobacterium supplemented (minimum dosage of 1E+10cfu/serving) vanilla flavored yogurt containing starter cultures: Streptococcus thermophilus and Lactobacillus delbrueckii subsp. Bulgaricus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Yogurt</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vanilla flavored yogurt containing starter cultures Streptococcus thermophilus and Lactobacillus delbrueckii subsp. Bulgaricus</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Probiotic strain of Bifidobacterium</intervention_name>
    <description>4 ounces (113g) of yogurt per day, for 14 days. Minimum Bifidobacterium dose of 1E+10 cfu/serving.</description>
    <arm_group_label>Bifidobacterium supplemented yogurt</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No Bifidobacterium</intervention_name>
    <description>4 ounces (113g) of yogurt per day, for 14 days. No bifidobacterium added.</description>
    <arm_group_label>Placebo Yogurt</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Being female&#xD;
&#xD;
          -  Ability to speak and write English or Spanish&#xD;
&#xD;
          -  Willingness to refrain from specified probiotic supplements, during the 12 week trial&#xD;
             (a list of prohibited products will be provided)&#xD;
&#xD;
          -  Have access to refrigeration and phone&#xD;
&#xD;
          -  Have a history of straining during bowel movements&#xD;
&#xD;
          -  Have a history of lumpy or hard stools&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of an allergy or intolerance to any ingredients in yogurt&#xD;
&#xD;
          -  Morbid obesity, defined as a BMI&gt;40&#xD;
&#xD;
          -  Having inflammatory bowel disease&#xD;
&#xD;
          -  Having a history of malabsorption syndrome&#xD;
&#xD;
          -  Immunodeficiency, such as HIV or currently receiving chemotherapy&#xD;
&#xD;
          -  Consumption of any medications used to treat, prevent or cure diarrhea in the last&#xD;
             month&#xD;
&#xD;
          -  Consumption of any medications used to treat, prevent or cure constipation in the last&#xD;
             month&#xD;
&#xD;
          -  Diabetes mellitus&#xD;
&#xD;
          -  Thyroid disorders, including hypo- or hyperthyroidism&#xD;
&#xD;
          -  History of gastric, small bowel or colonic resection&#xD;
&#xD;
          -  Documented history of gastric emptying disorder&#xD;
&#xD;
          -  Consumption of narcotics, antipsychotic medications, or verapamil in the last month&#xD;
&#xD;
          -  Known pelvic outlet obstruction&#xD;
&#xD;
          -  Antibiotic usage within 4 weeks of enrollment&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dan Merenstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Georgetown University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Caren Palese, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Georgetown University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Georgetown University Department of Family Medicine, Research Division</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <study_first_submitted>September 15, 2010</study_first_submitted>
  <study_first_submitted_qc>September 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2010</study_first_posted>
  <last_update_submitted>February 8, 2013</last_update_submitted>
  <last_update_submitted_qc>February 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

